Perindopril decreases angiotensin-converting enzyme 2 (ACE2) expression in human adipocytes exposed to SARS-CoV-2 S1 spike protein

• DOI: 10.52225/narra.v4i2.746
• Publication Date: 2024-05-03T04:22:05Z
• Authors: Primasitha M. Har...; Meity Ardiana; Hanestya O. Hermawan; Yeni Purnamasari; Faizal A. Anandita
• Keywords: Perindopril; Angiotensin-converting enzyme 2

The expression of angiotensin-converting enzyme 2 (ACE2) in the adipose tissues obese patients needs further study, as it may aid infection and serve a viral reservoir. There has been controversy over whether to use ACE inhibitors prevent coronavirus disease 2019 (COVID-19) severity. Perindopril, an ACE2 inhibitor, proposed; however, its relationship with COVID-19 not yet clear. aim this study was investigate effect perindopril reduce pro-inflammatory cytokine adipocytes exposed severe acute respiratory syndrome (SARS-CoV-2). Enzymatic isolation performed from male donor aged 30–50 years, then SARS-CoV-2 S1 spike protein. This also included human recombinant (hrsACE2) comparison perindopril. evaluated using ELISA. Our data indicated that Spike protein exposure increased significantly. Administration decreased (43.37 µg/mL) significantly compared positive group (80.31 (p<0.001). Perindopril administration IL-6 levels group(p<0.001). highlights could